247 related articles for article (PubMed ID: 8604486)
1. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
Busch MP; Korelitz JJ; Kleinman SH; Lee SR; AuBuchon JP; Schreiber GB
Transfusion; 1995; 35(11):903-10. PubMed ID: 8604486
[TBL] [Abstract][Full Text] [Related]
2. [Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy].
Kusendová K; Gavorník P; Sabaka P; Sviteková K
Vnitr Lek; 2016 Jan; 62(1):9-16. PubMed ID: 26967232
[TBL] [Abstract][Full Text] [Related]
3. Rare detection of hepatitis B and hepatitis C virus genomes by polymerase chain reaction in seronegative donors with elevated alanine aminotransferase.
Sankary TM; Yang G; Romeo JM; Ulrich PP; Busch MP; Rawal BD; Vyas GN
Transfusion; 1994 Aug; 34(8):656-60. PubMed ID: 8073480
[TBL] [Abstract][Full Text] [Related]
4. Limited utility of alanine aminotransferase screening of hepatitis C antibody-screened blood donors.
Cable R; Badon S; Pray C; Popovsky MA
Transfusion; 1997 Feb; 37(2):206-10. PubMed ID: 9051097
[TBL] [Abstract][Full Text] [Related]
5. Antibody to hepatitis-C-virus-related proteins in sera from alanine-aminotransferase-screened blood donors and prospectively studied recipients.
Widell A; Sundström G; Hansson BG; Moestrup T; Nordenfelt E
Vox Sang; 1991; 60(1):28-33. PubMed ID: 1647082
[TBL] [Abstract][Full Text] [Related]
6. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers.
Barrera JM; Bruguera M; Ercilla MG; Sánchez-Tapias JM; Gil MP; Costa J; Gelabert A; Rodés J; Castillo R
Ann Intern Med; 1991 Oct; 115(8):596-600. PubMed ID: 1909848
[TBL] [Abstract][Full Text] [Related]
7. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
Nübling CM; Chudy M; Volkers P; Löwer J
Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
[TBL] [Abstract][Full Text] [Related]
8. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes.
Mosley JW; Huang W; Stram DO; Nowicki MJ; Hollinger FB; Aach RD; Stevens CE; Barbosa LH; Nemo GJ
Transfusion; 1996 Sep; 36(9):776-81. PubMed ID: 8823449
[TBL] [Abstract][Full Text] [Related]
9. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis.
Baginski I; Chemin I; Hantz O; Pichoud C; Jullien AM; Chevre JC; Li JS; Vitvitski L; Sninsky JJ; Trepo C
Transfusion; 1992; 32(3):215-20. PubMed ID: 1557801
[TBL] [Abstract][Full Text] [Related]
10. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
Silverstein MD; Mulley AG; Dienstag JL
JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
[TBL] [Abstract][Full Text] [Related]
11. Correlation of hepatitis C RNA and serum alanine aminotransferase in hepatitis B and C seronegative healthy blood donors.
Ali N; Moiz B; Moatter T; Ahmed S; Adil SN; Khurshid M
Indian J Pathol Microbiol; 2010; 53(3):480-5. PubMed ID: 20699507
[TBL] [Abstract][Full Text] [Related]
12. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS).
Glynn SA; Kleinman SH; Schreiber GB; Busch MP; Wright DJ; Smith JW; Nass CC; Williams AE
JAMA; 2000 Jul; 284(2):229-35. PubMed ID: 10889598
[TBL] [Abstract][Full Text] [Related]
13. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group.
Busch MP; Dodd RY; Lackritz EM; AuBuchon JP; Birkmeyer JD; Petersen LR
Transfusion; 1997 Oct; 37(10):1003-11. PubMed ID: 9354817
[TBL] [Abstract][Full Text] [Related]
14. Predonation screening of candidate donors and prevention of window period donations.
Lieshout-Krikke RW; Zaaijer HL; van de Laar TJ
Transfusion; 2015 Feb; 55(2):373-8. PubMed ID: 25130605
[TBL] [Abstract][Full Text] [Related]
15. Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors.
Tsai JF; Jeng JE; Ho MS; Wang CS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Liver; 1997 Feb; 17(1):24-9. PubMed ID: 9062876
[TBL] [Abstract][Full Text] [Related]
16. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg.
Chung HT; Lee JS; Lok AS
Hepatology; 1993 Nov; 18(5):1045-9. PubMed ID: 7693569
[TBL] [Abstract][Full Text] [Related]
17. History of posttransfusion hepatitis.
Tobler LH; Busch MP
Clin Chem; 1997 Aug; 43(8 Pt 2):1487-93. PubMed ID: 9265899
[TBL] [Abstract][Full Text] [Related]
18. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
19. Determination of alanine aminotransferase in blood donor screening--evidence of its usefulness in the prevention of post-transfusion hepatitis.
Khouri ST; Lopes EP; Perez RM; Figueiredo VM; Lanzoni VP; Silva AE; Ferraz ML
Clin Lab; 2004; 50(5-6):291-4. PubMed ID: 15209437
[TBL] [Abstract][Full Text] [Related]
20. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.
Kim MJ; Park Q; Min HK; Kim HO
BMC Infect Dis; 2012 Jul; 12():160. PubMed ID: 22817275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
